Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Improving the efficacy and stability of coronary reperfusion following thrombolysis: Exploring the thrombin hypothesis


A major assumption in the treatment of patients with acute myocardial infarction (MI) implies that the speed of coronary arterial reperfusion correlates directly with the overall extent of myocardial salvage, and that the extent of myocardial salvage, in turn, determines the absolute reduction in patient mortality. While a growing experience has made it clear that myocardial salvage-independent (time-independent) mechanisms of benefit also exist, few would argue with the hypothesis that the greatest benefit derived from coronary thrombolysis occurs with early (time-dependent) treatment. Thus, improvements in the efficacy of reperfusion and the stability of reperfusion are likely to have considerable impact on patient outcome.

This is a preview of subscription content, log in to check access.


  1. 1.

    Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL. Does Thrombolysis in Myocardial Infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study.J Am Coll Cardiol 1992;19:1–10.

  2. 2.

    Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct-related artery after thrombolysis for acute myocardial infarction on short term mortality: A retrospective analysis of four German multicenter studies.J Am Coll Cardiol, in press.

  3. 3.

    Lincoff AM, Ellis SG, Galeana A, Sigmon KN, Lee KL, Rosenschein U, for the TAMI Study Group. Is a coronary artery with TIMI grade 2 flow “patent”? Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trial (abstract).Circulation 1992;86(Suppl I):I-268.

  4. 4.

    Wall T, Mark DB, Califf RM, et al. Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: A qualitative and quantitative angiographic study.Am J Cardiol 1989;63:423–428.

  5. 5.

    Grines CL, Topol EJ, Bates ER, Juni JE, Walton JA, O'Neill WW. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: Prediction of clinical outcome.Am Heart J 1988;115:1–7.

  6. 6.

    Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction.Circulation 1992;85:1699–1705.

  7. 7.

    Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults.Atherosclerosis 1989;9(Suppl I):I19-I32.

  8. 8.

    Farrell M, Fuster V. Mechanisms of acute myocardial infarction. In: Becker RC, ed.The Modern Era of Coronary Thrombolysis. Boston: Kluwer Academic Publishers, 1994:1–13.

  9. 9.

    Mizuno K, Satomura K, Miy A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes.N Engl J Med 1992;326:287–291.

  10. 10.

    Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture.J Am Coll Cardiol 1994;23:1562–1569.

  11. 11.

    Carney RJ, Murphy GA, Brandt TR, et al. for The RAA MI Study Investors: Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction.J Am Coll Cardiol 1992;20:17–23.

  12. 12.

    Gotsman M, Rosencheck S, Nassar H, et al. Angiographic findings in the coronary arteries after thrombolysis in acute myocardial infarction.Am J Cardiol 1992;70:715–723.

  13. 13.

    Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction.N Engl J Med 1987;317:1055–1059.

  14. 14.

    Anderson JL, Becker LC, Sorensen S, et al. Anistreplase versus alteplase in acute myocardial infarction: Comparative effects on left ventricular function, morbidity and oneday coronary artery patency.J Am Coll Cardiol 1992;20:1753–1766.

  15. 15.

    Johns JA, Gold HK, Linbach RC, et al. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction.Circulation 1988;78:546–556.

  16. 16.

    Rogers WH, Caim DS, Gore JM, et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator.Circulation 1990;81:1457–1476.

  17. 17.

    Baim DS, Diver DJ, Feit F, et al. Coronary angioplasty performed within the thrombolysis in myocardial infarction II study.Circulation 1992;85:93–105.

  18. 18.

    Bosch X, Theroux P, Waters DD, et al. Early postinfarction ischemia: Clinical angiographic and prognostic significance.Circulation 1987;75:98–995.

  19. 19.

    Bosch, Therous MD, Pelletier GB, et al. Clinical and angiographic features and prognostic significance of early postinfarction angina with and without electrocardiographic signs of transient ischemia.Am J Med 1991;91:493–501.

  20. 20.

    Arnold AER, Simoons ML, van De Werf F, et al. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction.Circulation 1992;86:11–120.

  21. 21.

    Kereiakes DJ, Topol EJ, George BS, et al. Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion.J Am Coll Cardiol 1991;17:304–312.

  22. 22.

    Gertz SD, Uretzky G, Wajnberg RS, et al. Endothelial cell damage and thrombus formation after partial arterial construction. Relevance to the role of coronary artery spasm in the pathogenesis of myocardial infarction.Circulation 1981;63:476–486.

  23. 23.

    Nelson E, Gertz SD, Forbes MS, et al. Endothelial lesions in the aorta of egg yolk-fed miniature swine: A study by scanning and transmission electron microscopy.Exp Mol Pathol 1976;25:208–220.

  24. 24.

    Fry DL. Acute vascular endothelial changes associated with increased blood velocity gradients.Circ Res 1968;22:165–197.

  25. 25.

    Ouyang P, Shapiro EP, Gottlieb SO. Thrombolysis in postinfarction angina.Am J Cardiol 1991;68:124B-199B.

  26. 26.

    Shapiro EP, Brinker JA, Gottlieb SO, Guzman PA, Bulkley BH. Intracoronary thrombolysis 3 to 13 days after acute myocardial infarction for postinfarction angina pectoris.Am J Cardiol 1985;5:1453–1458.

  27. 27.

    Nakagawa S, Hanada Y, Koiwaya Y, Tanaka K. Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation.Circulation 1988;78:1335–1344.

  28. 28.

    Serruys PW, Arnold AER, Brower RW, et al. Effects of continued rtPA administration in acute myocardial infarction—A quantitative coronary angiography study of a randomized trial.Eur Heart J 1987;8:1172–1181.

  29. 29.

    Harrison DG, Ferguson DW, Collins SM, et al. Rethrombosis after reperfusion with streptokinase: Importance of geometry of residual lesions.Circulation 1984;69:991–999.

  30. 30.

    Gash AK, Spann JF, Sherry S, et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction.Am J Cardiol 1986;61:381–384.

  31. 31.

    Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: Platelet grow at the apex of stenotic severely injured vessel wall. Experimental study in the pig model.J Clin Invest 1990;84:1134–1144.

  32. 32.

    Lassila R, Badimon JJ, Vallabhajosula S, Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenosis on thrombus growth.Arteriosclerosis 1990;134:1087–1097.

  33. 33.

    Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.N Engl J Med 1981;304:685–691.

  34. 34.

    Fitzgerald DJ, Catella RL, Fitzgerald GA. Platelet activation in unstable coronary disease.N Engl J Med 1986;315:983–989.

  35. 35.

    van Den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina complex coronary lesion morphology.Circulation 1989;79:116–124.

  36. 36.

    Davies MJ. Successful and unsuccessful coronary thrombolysis.Br Heart J 1986;61:381–384.

  37. 37.

    Richardson SG, Callen D, Morton P, et al. Pathological changes after intravenous streptokinase treatment in eight patients with acute myocardial infarction.Br Heart J 1989;61:390–395.

  38. 38.

    Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type I.Circulation 1988;78:1431–1442.

  39. 39.

    Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated blood.Thromb Res 1989;55:635–643.

  40. 40.

    Francis CW, Markham RF, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives.J Lab Clin Med 1983;102:200–230.

  41. 41.

    Weitz JI, Cruickshang MK, Thong B, et al. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.J Clin Invest 1988;82:1700–1707.

  42. 42.

    Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis.J Am Coll Cardiol 1986;7:1255–1262.

  43. 43.

    Griffin JT, Cochran LHG. Recent advances in the understanding of contact activation reactions.Semin Thromb Hemost 1979;5:254–273.

  44. 44.

    Haskel DJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor.Circulation 1991;84:821–827.

  45. 45.

    Lee CD, Mann KG. The activation of human coagulation factor V by plasmin.Blood 1989;73:185–190.

  46. 46.

    Greenberg JP, Packham MA, Guccione MA. The effect of pretreatment of human or rabbit platelets with chymotrypsin on their response to human fibrinogen and aggregating agents.Blood 1979;54:753–765.

  47. 47.

    Guccione MA, Kinlough-Tathbone RL, Packham MA, et al. Effect of plasmin on rabbit platelets.Thromb Haemost 1985;53:8–14.

  48. 48.

    Schafer AI, Mars AK, Ware JA. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin.J Clin Invest 1986;78:73–79.

  49. 49.

    Lucore CL, Fujii S, Sobel BE. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.Circulation 1989;79:1204–1213.

  50. 50.

    Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.Circulation 1988;77:660–668.

  51. 51.

    Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type I activity in plasma by thrombosis and by thrombolysis.J Am Coll Cardiol 1991;18:1547–1554.

  52. 52.

    Selike FW, Wuillen JE, Brooks LA, Harrison DG. Endothelial modulation of the coronary vasculature in vessels perfused via mature collaterals.Circulation 1990;81:1938–1947.

  53. 53.

    Weidinger FF, McLenachan JM, Cybulsky MI, et al. Hyperscholesterolemia enhances macrophage recruitment and dysfunction of regenerated endothelium after balloon injury of the rabbit iliac artery.Circulation 1991;84:755–767.

  54. 54.

    Tsao PS, Aoki N, Leger DJ, Johnson G III, Lefer AM. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat.Circulation 1990;82:1402–1412.

  55. 55.

    Pelc LR, Garancis JC, Gross GJ, Warltier DC. Alteration of endothelium dependent distribution of myocardial blood flow after coronary occlusion and reperfusion.Circulation 1990;81:1928–1936.

  56. 56.

    Forman MB, Puett DW, Cirmani R. Endothelial and myocardial injury during ischemia and reperfusion: Pathogenesis and therapeutic implication.J Am Coll Cardiol 1989;13:450–459.

  57. 57.

    Perason PJ, Scharff HV, Vanhoutte PM. Long term impairment of endothelial dependent relaxations to aggregating platelets after reperfusion injury in canine coronary arteries.Circulation 1990;81:1921–1926.

  58. 58.

    Kloner RA, Fiacommelli F, Alker KJ, Hale SL, Mathews R, Bellows S. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion.Circulation 1991;84:1958–1972.

  59. 59.

    Gasic AC, McGuire F, Krater S, et al. Hydrogen peroxide pretreatment of perfused canine vessels induces ICAM-1 and CD-18 dependent neutrophil adherence.Circulation 1991;84:2154–2166.

  60. 60.

    Gelehter TD, Lznycer-Laszuck R. Thrombin induction of plasminogen activator inhibitor in cultured human endothelial cells.J Clin Invest 1986;77:165–169.

  61. 61.

    Konkle BA, Ginsburg D. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen of activator inhibitor-I expression.J Clin Invest 1988;82:579–585.

  62. 62.

    Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombosis.Circulation 1985;71:912–918.

  63. 63.

    Becker RC, Bovill EG, Corrao JM, Ball SP, Ault K, Mann KG, Tracy RP. Thrombin and platelet activity do not correlate in unstable angina and non-Q wave myocardial infarction (abstr).Circulation 1993, in press.

  64. 64.

    Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction.Circulation 1991;83:937–944.

  65. 65.

    Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis.J Am Coll Cardiol 1986;7:1255–1262.

  66. 66.

    Gulba DC, Daniel WG, Simon R, et al. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty.J Am Coll Cardiol 1990;16:563–568.

  67. 67.

    Eisenberg PR, Abendschein DR, Becker RC, Loscalzo J, Sobel BE and the TIMI Investigators. Lack of suppression of thrombin activity in vivo: A determination of failure of recanalization (abstr).J Am Coll Cardiol 1993;21(Suppl A):464A.

  68. 68.

    Ofosu FA, Gray E. Mechanisms of action of heparin: Applications to the development of derivatives of heparin and heparinoids with antithrombin properties.Semin Thromb Haemost 1988;14:9–17.

  69. 69.

    Gallino A, Haeberli A, Hess T, Mombelli G, Straub PW. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: Effects of intravenous and subcutaneous low dose heparin.Am Heart J 1986;12:285–290.

  70. 70.

    Bovill EG, Granger CB, Ross A, Lambrew C, Becker RC, Keeler G, Tracy RP. Thrombin inhibition is more closely related to PTT than to heparin level after thrombolysis and heparin therapy (abstr).J Am Coll Cardiol 1993;31(Suppl A):137A.

  71. 71.

    Rapold H, de Bone D, Arnold AER, et al. Plasma fibrinopeptide A levels in patients with active myocardial infarction treated with alteplase.Circulation 1992;85:928–934.

  72. 72.

    Heras M, Chesebro JH, Penny WJ, et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model.Circulation 1988;78:654–660.

  73. 73.

    Prager NA, Torr-Brown SR, Sobel BE, Abendschien DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.J Am Coll Cardiol 1993;32:296–301.

  74. 74.

    Hsia J, Hamilton W, Kleiman N, et al. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction.N Engl J Med 1990;323:1433–1438.

  75. 75.

    Bleisch SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.Am J Cardiol 1990;66:1412–1417.

  76. 76.

    de Bono DP, Simoons ML, Tjissen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomized double blind European Cooperative Study Group trial.Br Heart J 1992;67:122–128.

  77. 77.

    Hsia J, Kleiman N, Auguirre F, et al. Heparin induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency.J Am Coll Cardiol 1992;20:31–35.

  78. 78.

    Arnout J, Simoons M, de Bono D, et al. Correlation between level of heparinization and patency of the infarct related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).J Am Coll Cardiol 1992;20:513–519.

  79. 79.

    Thompson PL, Aylward PE, Federman J, et al. for the National Heart Foundation of Australia Coronary Thrombolysis Group. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue type plasminogen activator for acute myocardial infarction.Circulation 1991;83:1534–1542.

  80. 80.

    GUSTO Investigators: Global utilization of streptokinase and tPA for occluded coronary arteries.N Engl J Med 1993;329:673–682.

  81. 81.

    Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.Blood 1988;72:616–620.

  82. 82.

    Eisenberg PR, Miletich JP, Sobel BE, Jaffe DS. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator.Thromb Res 1988;50:707–717.

  83. 83.

    Winters KJ, Santoro SA, Miletich JP, Eisenberg PR. Relative importance of thrombin compared with plasminmediated platelet activation in response to plasminogen activation with streptokinase.Circulation 1991;84:1552–1560.

  84. 84.

    Melandri G, Branzi A, Semprini F, Cervi V, Nassareno G, Bagnani B. Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin.Br Heart J 1990;64:118–120.

  85. 85.

    The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction.N Engl J Med 1993;329:1615–1622.

  86. 86.

    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2.Lancet 1988;3:349–360.

  87. 87.

    The SCATI (Studio Sulla Calciparina Nell" Angina e Nella Thrombisi Ventricolare Nell' Infarcto) Group.Lancet 1989;11:182–187.

  88. 88.

    Gruppo Italiano Per Los Studio Bella Sopravvivenza Nell'Infarcto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction.Lancet 1990;336:65–75.

  89. 89.

    The International Study Group. In hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin.Lancet 1990;336:71–75.

  90. 90.

    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction.Lancet 1992;339:1–18.

  91. 91.

    O'Connor CM, Meese R, Carney R, et al. for the Duke University Clinical Cardiology Study Group. A randomised trial of intravenous heparin in conjunction with anistreplase (APSAC) in acute myocardial infarction: The DUCCS I Study.J Am Coll Cardiol, 1994;23:11–18.

  92. 92.

    Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells.Thromb Res 1978;12:773–782.

  93. 93.

    Mahadoo J, Heibert L, Jaques LB. Vascular sequestration of heparin.Thromb Res 1977;12:79–90.

  94. 94.

    Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance.Thromb Haemost 1992;67:639–643.

  95. 95.

    Becker RC, Corrao JM, Bovill EG, et al. Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormality.Am Heart J 1990;119:1254–1261.

  96. 96.

    Shapiro G, Huntzinger SW, Wilson JE. Variation among commercial activated parietal thromboplastin time reagents in response to heparin.Am J Clin Pathol 1977;67:477–480.

  97. 97.

    Becker RC, Corrao JM, Ball SP, Gore JM. A comparison of heparin strategies after thrombolytic therapy.Am Heart J 1993;126:750–752.

  98. 98.

    Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin today.Arch Intern Med 1991;151:333–337.

  99. 99.

    Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.Arch Intern Med 1992;152:1589–1595.

  100. 100.

    Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial.Ann Intern Med 1993;119:874–881.

  101. 101.

    Becker RC, Cyr J, Corrao JM, Ball SP. Bedside coagulation monitoring in heparinized patients with active thromboembolic disease: A coronary care unit experience.Am Heart J 1994;128:719–723.

  102. 102.

    Mirshahi M, Soria J, Soria C, et al. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.Blood 1989;3:1025–1030.

  103. 103.

    Marki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins.Thromb Haemost 1990;64:344–348.

  104. 104.

    Connor CP, McCabe CH, Henry TD, et al. for the TIMI 5 Investigators. A pilot trial of recombinant desulfato hirudin compared to heparin in conjunction with tissue plasminogen activator in aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI 5) Trial.J Am Coll Cardiol 1994;23:993–1003.

  105. 105.

    Loscalzo J, Abdenschein D, Eisenberg P, et al. for the TIMI 5 Investigators. Comparative effects of heparin and hirudin on fibrinolytic and thrombotic activities during tissue type plasminogen activator therapy.Circulation 1993;88(Suppl I):I200.

  106. 106.

    Glusa E. Vascular effects of thrombin.Semin Thromb Hemost 1992;18:296–304.

  107. 107.

    DeMichele MAA, Minnear FL. Modulation of vascular endothelial permeability by thrombin.Semin Thromb Hemost 1992;18:287–295.

  108. 108.

    Galdal KS, Evensen SA. Effects of divalent cations and various vasoactive and hemostatically active agents on the integrity of monolayers of cultured human endothelial cells.Thromb Res 1981;21:273–284.

  109. 109.

    Garcia JHN, Siflinger-Birnboim A, Bizios R, Del Vecchio PJ, Fenton II JW, Malik AB. Thrombin induced increase in albumin permeability across the endothelium.J Cell Physiol 1986;128:96–104.

  110. 110.

    Killackey JJF, Johnston MG, Moval HZ. Increased permeability of micro-carrier cultured endothelial monolayers in response to hitamine and thrombin: A model for the in vitro study of increased vasopermeability.Am J Pathol 1989;122:50–61.

  111. 111.

    Laposata M, Dovnarksy DK, Shin HS. Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro.Blood 1983;62:549–556.

  112. 112.

    Fenton II JW. Thrombin bioregulatory functions.Adv Clin Enzymol 1988;6:186–193.

  113. 113.

    Rudd AM, Johnstone MT, Rabbani LE, George D, Ware A, Loscalzo J. Thrombolytic therapy causes an increase in vascular permeability that is reversed by 1-deamino-8-D-vasopressin.Circulation 1991;84:2568–2573.

  114. 114.

    Lee LV, McCabe CH, Antman EM, et al. for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the TIMI 6 trial.Am J Cardial 1994, in press.

  115. 115.

    Lidon R-M, Theroux P, Lesperance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.Circulation 1994;89:1567–1572.

Download references

Author information

Correspondence to Richard C. Becker.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Becker, R.C. Improving the efficacy and stability of coronary reperfusion following thrombolysis: Exploring the thrombin hypothesis. J Thromb Thrombol 1, 133–144 (1995). https://doi.org/10.1007/BF01062570

Download citation

Key words

  • Thrombolysis
  • coronary perfusion